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Guest Editorial
Beta-blockers: A Second Rate Treatment for Hypertension?
BERNARD M Y CHEUNG
From Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of
Hong Kong, Queen Mary Hospital, Hong Kong SAR

Hypertension is a major risk factor for stroke and
myocardial infarction. Lowering blood pressure by
5-6 mmHg reduces the stroke risk by 38%. 1 It is
astonishing that the treatment of hypertension is so
beneficial when the efficacy of currently available
antihypertensive drugs is so modest. Thus, any drug,
which lowers blood pressure and is safe, is approved
for clinical use. In the last decade, large clinical trials
have been conducted to compare antihypertensive drugs
in terms of cardiovascular outcome.2,3 One of the latest
trials was the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT), the results of the blood pressure
lowering arm of which have recently been reported at
the American College of Cardiology Annual Scientific
Session.4 The database is not complete yet, but the
preliminary results already show that the amlodipineperindopril arm (new drugs) had better outcomes than
the diuretic-beta-blocker arm (old drugs). Furthermore,
there were more new cases of diabetes in the latter arm.
The results of ASCOT were unexpected, because
previous trials of old versus new drugs had been a tie.5-7 In
the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT), 8 diuretics
performed as well as amlodipine and lisinopril, but
because thiazide diuretics have been in use for a long
time and are economical, they are promoted as first line
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treatment in the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC7).9 However,
beta-blockers are not advocated as first line treatment
in JNC7. In the British guidelines, there are explicit
reservations regarding beta-blockers.10 In older trials on
hypertension, beta-blockers were used together with
thiazide diuretics and so took a share of the credit for
the benefits shown.1 On their own, they are less than
impressive.11 In the Medical Research Council trial of
treatment of hypertension in older adults, beta-blockers
were no better than placebo and significantly inferior to
diuretics.12 In the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE), atenolol was
inferior to losartan with regard to stroke, although it was
non-significantly better than losartan in terms of
myocardial infarction.13 A recent meta-analysis showed
that atenolol performs consistently less well than other
antihypertensive drugs in clinical trials.14
ASCOT was an unequal race between old warhorses and young thoroughbreds. Diuretics and betablockers need to be used at low doses, limiting their
blood pressure lowering effect. These drugs also
worsen the metabolic profile whereas angiotensinconverting enzyme inhibition prevents diabetes. 15
Amlodipine is a very efficacious antihypertensive
agent.16,17 Small differences in blood pressure control
can be translated to significant differences in clinical
outcome, as in the Valsartan Antihypertensive Longterm Use Evaluation (VALUE) trial.18,19 Amlodipine
also has an anti-atherosclerotic effect in carotid and
coronary arteries.20,21
Beta-blockers remain valuable in the treatment
of angina pectoris and myocardial infarction, and their
use in heart failure clearly reduces mortality.22 They are
contraindicated in asthma and peripheral vascular
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disease. In the light of the latest evidence, the use of a
beta-blocker should not be a reflex but a carefully
considered action. The American and World Health
Organization guidelines may require revision, 9,23
whereas the European guidelines characteristically give
equal weight to each antihypertensive drug class.24 The
British guidelines hold up rather well.10 The British
Hypertension Society, adopting the Cambridge ABCD
rule, proposes that beta-blockers are less suitable as firstline treatment in the elderly.25 I would not discard them
for the moment, not least because they are surprisingly
the best tolerated antihypertensive drug class apart from
angiotensin receptor blockers.26 The majority of patients
require a number of drugs to reach current blood pressure
targets (140/90 mmHg and lower targets for patients with
diabetes or nephropathy).9,10,23,24 Beta-blockers may
therefore be one of the drugs used to attain good blood
pressure control. 27 Drug companies are keen to
emphasise and exploit small differences between drugs,
but these pale into insignificance when compared to the
paramount importance of good blood pressure control.
Beta-blockers are out of favour for hypertension for the
moment, but the full results of ASCOT are still awaited.
The pendulum may swing this way and that way from
time to time, but it will finally come to rest in the middle.
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